BioMarin develops and commercializes therapies for rare diseases. Products include Vimizim, Naglazyme, Kuvan, Palynziq, Brineura, Voxzogo, and Aldurazyme. The company also develops Roctavian for severe hemophilia A. It serves specialty pharmacies, hospitals, and government agencies in the US, Europe, Latin America, and internationally.
| Indicator | Value |
|---|---|
| PER | 24.7 |
| EV/EBITDA | 15.9 |
| Price/Free Cash Flow' | 22.1 |
| ROIC | 9.1% |
| Net Debt/EBITDA | -0.5 |